Original contribution| Volume 41, ISSUE 2, P135-141, August 2011

Download started.


Is the Drip-and-Ship Approach to Delivering Thrombolysis for Acute Ischemic Stroke Safe?


      Background: The drip-and-ship method of treating stroke patients may increase the use of tissue plasminogen activator (t-PA) in community hospitals. Objective: The safety and early outcomes of patients treated with t-PA for acute ischemic stroke (AIS) by the drip-and-ship method were compared to patients directly treated at a stroke center. Methods: The charts of all patients who were treated with intravenous (i.v.) t-PA at outside hospitals under the remote guidance of our stroke team and were then transferred to our facility were reviewed. Baseline NIHSS (National Institutes of Health Stroke Scale) scores, onset-to-treatment (OTT), and arrival-to-treatment (ATT) times were abstracted. The rates of in-hospital mortality, symptomatic hemorrhage (sICH), early excellent outcome (modified Rankin Scale [mRS] ≤ 1), and early good outcome (discharge home or to inpatient rehabilitation) were determined. Results: One hundred sixteen patients met inclusion criteria. Eighty-four (72.4%) were treated within 3 h of symptom onset. The median estimated NIHSS score was 9.5 (range 3–27). The median OTT time was 150 min, and the median ATT was 85 min. These patients had an in-hospital mortality rate of 10.7% and sICH rate of 6%. Thirty percent of patients had an early excellent outcome and 75% were discharged to home or inpatient rehabilitation. When these outcome rates were compared with those observed in patients treated directly at our stroke center, there were no statistical differences. Conclusions: In this small retrospective study, drip-and-ship management of delivering i.v. t-PA for AIS patients did not seem to compromise safety. However, a large prospective study comparing drip-and-ship management to routine care is needed to validate the safety of this approach to treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Katzan I.L.
        • Furlan A.J.
        • Lloyd L.E.
        • et al.
        Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
        JAMA. 2000; 283: 1151-1158
        • Reed S.D.
        • Cramer S.C.
        • Blough D.K.
        • Meyer K.
        • Jarvik J.G.
        Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals.
        Stroke. 2001; 32: 1832-1840
        • Chan Y.F.
        • Kwiatkowski T.G.
        • Rella J.G.
        • et al.
        Tissue plasminogen activator for acute ischemic stroke: a New York city emergency medicine perspective.
        J Emerg Med. 2005; 29: 405-408
        • Kothari R.U.
        • Brott T.
        • Broderick J.P.
        • Hamilton C.A.
        Emergency physicians.
        Stroke. 1995; 26: 2238-2241
        • Morgenstern L.B.
        • Lisabeth L.D.
        • Mecozzi A.C.
        • et al.
        A population-based study of acute stroke and TIA diagnosis.
        Neurology. 2004; 62: 895-900
        • Rymer M.M.
        • Thurtchley D.
        • Summers D.
        Expanded modes of tissue plasminogen activator delivery in a comprehensive stroke center increases regional acute stroke interventions.
        Stroke. 2003; 34: e58-e60
        • Silverman I.E.
        • Beland D.K.
        • Chhabra J.
        • McCullough L.D.
        The “drip-and-ship” approach: starting IV t-PA for acute ischemic stroke at outside hospitals prior to transfer to a regional stroke center.
        Conn Med. 2005; 69: 613-620
        • Acker 3rd, J.E.
        • Pancioli A.M.
        • Crocco T.J.
        • et al.
        Implementation strategies for emergency medical services within stroke systems of care: a policy statement from the American Heart Association/American Stroke Association Expert Panel on Emergency Medical Services Systems and the Stroke Council.
        Stroke. 2007; 38: 3097-3115
        • Kasner S.E.
        • Chalela J.A.
        • Luciano J.M.
        • et al.
        Reliability and validity of estimating the NIH stroke scale score from medical records.
        Stroke. 1999; 30: 1534-1537
        • Larrue V.
        • von Kummer R.R.
        • Muller A.
        • Bluhmki E.
        Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
        Stroke. 2001; 32: 438-441
      1. Tissue plasminogen activator for acute ischemic stroke.
        N Engl J Med. 1995; 333: 1581-1587
        • Smith W.S.
        Can emergency medicine physicians accurately identify i.v. t-PA eligible acute stroke patients?.
        Neurocrit Care. 2007; 7: 101-102
        • Mecozzi A.C.
        • Brown D.L.
        • Lisabeth L.D.
        • et al.
        Determining intravenous rt-PA eligibility in the Emergency Department.
        Neurocrit Care. 2007; 7: 103-108
        • Lovblad K.O.
        • Laubach H.J.
        • Baird A.E.
        • et al.
        Clinical experience with diffusion-weighted MR in patients with acute stroke.
        AJNR Am J Neuroradiol. 1998; 19: 1061-1066
        • Saver J.L.
        Time is brain-quantified.
        Stroke. 2006; 37: 263-266
        • Stroke Unit Trialists' Collaboration
        Organised inpatient (stroke unit) care for stroke.
        Cochrane Database Syst Rev. 2002; (CD000197)